Medable Inc. and Vault Health, Inc. have announced that they’re teaming up to integrate Vault’s knowledge in diagnostics, logistics, and remote care services with Medable’s software platform for decentralized clinical trials. The partnership builds on a shared commitment to bring trials closer to patients via remote monitoring and high-touch patient services—helping make clinical trials more inclusive and accessible.
The two companies will combine Medable’s software-as-a-service platform with Vault’s tech-enabled operational capabilities to provide a unified experience for patients, sites, and clinical trial sponsors. The partnership will enable sponsors to offer Vault home testing and diagnostics, home healthcare visits and TeleVisits, virtual site capabilities, and related logistics, scheduling, and status tracking.
Medable and Vault Health Partner to Expand Direct-to-Patient Testing and eCare for DCTs
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.